Covalent Irreversible Inhibitors of Tetracycline Destructases.

Area of Science:

• Medicinal Chemistry
• Biochemistry
• Microbiology

Background:

• Antibiotic resistance poses a significant global health threat, driven by mechanisms like enzymatic inactivation of drugs.
• Tetracycline destructases (TDases), homologous to flavin monooxygenases, are emerging enzymes that inactivate tetracycline antibiotics.
• Developing inhibitors of these resistance enzymes is crucial for combination therapies to combat bacterial resistance.

Purpose of the Study:

• To design, synthesize, and characterize the first covalent irreversible inhibitors of TDases.
• To explore the mechanism of inhibition and evaluate their efficacy in restoring antibiotic activity.

Main Methods:

• Chemical synthesis of anhydrotetracycline (aTC) derivatives with reactive warheads (Mannich reaction).
• Biochemical characterization of inhibitor potency and mechanism against Type 1 (TetX6, TetX7) and Type 2 (Tet50) TDases.
• Mechanistic studies using nonspecific flavin monooxygenase inhibitors and mass spectrometry to probe FAD cofactor interaction.
• In vitro evaluation of inhibitor efficacy in restoring tetracycline activity against resistant *E. coli*.

Main Results:

• Novel aTC-based covalent inhibitors (compounds 3-5) were synthesized and demonstrated potent inhibition of both Type 1 and Type 2 TDases.
• Inhibition of Type 2 TDases was time-dependent and irreversible, consistent with covalent modification of the FAD cofactor, enhanced by blue light.
• Inhibitors successfully restored tetracycline activity against *E. coli* overexpressing TDases at low concentrations (2 μg/mL).

Conclusions:

• Covalent inhibition of TDases via FAD cofactor trapping is a viable strategy to overcome antibiotic resistance.
• The developed inhibitors represent a promising new class of therapeutics for combination therapy against resistant bacterial infections.
• Understanding the distinct inhibition mechanisms for different TDase types can guide future drug design.